Meta Information

ID:thymosin-alpha-1

Name:Thymosin Alpha-1

Schema Version:1.5

Alternate Names

• Zadaxin
• Thymalfasin
• TA1

Active Compound

thymosin alpha-1

Intervention Type

therapeutic_agent

Delivery

Route:

subcutaneous_injection

Scope:

• systemic

Regulatory Status

• us:compounded_drug
• global:rx_drug

Indication

Focus:

healthspan

Description:

Modulates T-cell function and general immune response to counter immunosenescence, with established roles in certain viral infections and cancers.

Typical Protocol

• For healthspan-focused immune modulation, doses typically range from 0.8 mg to 3.2 mg administered via subcutaneous injection 1-2 times per week.
• For approved indications (e.g., chronic hepatitis B), standard protocols include 1.6 mg subcutaneous injection twice weekly for 6-12 months.

Expected Cost Mean

Low Cost:

200

High Cost:

600

Cost Type:

monthly

Description:

Cost for compounded peptide, generally not insurance-covered for healthspan uses.

Summary

Thymosin alpha-1 is a naturally occurring peptide produced by the thymus gland, essential for immune system development and function. It primarily enhances T-cell maturation and activity, particularly CD4+ helper T cells, cytotoxic T cells, and natural killer cells. By bolstering cellular immunity, it may help combat immunosenescence, the age-related decline in immune function, potentially improving resilience against infections and contributing to healthy aging.

Purpose

Enhances T-cell immunity to counter age-related immune decline.

Card Summary

Thymosin alpha-1 boosts T-cell function, potentially mitigating age-related immune decline and improving resilience.

Drug Class

immunomodulator

Drugs In Class

Empty Array

Impact

Score:

5.5

Justification:

Targeted immune modulation with potential for age-related immunosenescence benefits.

Evidence

Grade:

B

Score:

6.5

Justification:

Robust human data for specific diseases; limited direct healthspan RCTs.

Safety

Score:

4.5

Justification:

Generally well-tolerated; potential for injection site reactions, flu-like symptoms.

Flags

• Not FDA approved for general healthspan or anti-aging in the US.
• Requires subcutaneous injection, necessitating proper sterile technique and medical oversight.
• May interact with other immunosuppressants or immune-stimulants, requiring caution.
• Long-term safety data in healthy individuals for healthspan applications is limited.
• Contraindicated in individuals with hypersensitivity or autoimmune diseases where immune stimulation is undesirable.

Verdict

Modulates immunity; potential for healthy aging, requires injection.